News
Article
Author(s):
This review of the latest dermatologic studies includes insights into differences in vitamin D levels in rosacea versus healthy individuals, psychosocial determinants and atopic dermatitis outcomes, and more.
A case–control study conducted in Iran compared vitamin D levels between 31 patients with rosacea and 31 healthy controls. Although mean vitamin D levels were higher in the rosacea group (29.9 ng/mL) than in controls (24.5 ng/mL), the difference was not statistically significant. Subgroup analysis by gender and rosacea severity also revealed no significant associations. Logistic regression adjusted for age showed no link between vitamin D levels and rosacea, suggesting no meaningful relationship between vitamin D status and the presence or severity of the condition.1
A retrospective cross-sectional study of 908 children with atopic dermatitis (AD) at a pediatric center in Melbourne found that those from at-risk groups—such as rural, culturally diverse, First Nations, socioeconomically disadvantaged, or vulnerable backgrounds—had significantly more severe disease (43.8% vs 28.3%) and greater health care use, including higher hospitalization and medication rates. Multivariate analysis showed these children had over 4 times the odds of severe AD and nearly 3 times the rate of hospitalizations compared to controls.2
A clinical report highlighted how erythema may present differently in patients with skin of color, often appearing as brown or purple patches that are easily mistaken for post-inflammatory hyperpigmentation (PIH). Through the use of dermoscopy, clinicians can distinguish erythema from PIH by identifying a positive blanching effect—seen in inflammatory conditions like AD but absent in pigmentary disorders.3
A recent study in Chinese patients with refractory vitiligo and moderate to severe AD found that combining upadacitinib with 308-nm excimer laser therapy significantly improved outcomes. After 4 months, patients achieved a 55% reduction in Vitiligo Area Scoring Index, with the most notable repigmentation occurring on the face and neck (>70%). The hands and feet were least responsive. Improvements were also seen in AD severity (SCORAD ↓41.89%) and quality of life (DLQI ↓49.12%). No serious adverse events occurred.4
A retrospective study evaluated the use of VYC-12, a high–molecular weight hyaluronic acid injectable, in 15 adults with facial inflammatory skin conditions or aging-related concerns in Japan. Among 10 patients with treatment-resistant AD, acne vulgaris, or rosacea, VYC-12 significantly reduced skin redness and improved hydration over a 4-month period. All participants reported satisfaction with outcomes, and no adverse events occurred.5
References
What new studies have you been involved with or authored? Share with us by emailing DTEditor@mmhgroup.com for an opportunity to be featured.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.